1
|
Protein deposition on contact lenses: The past, the present, and the future. Cont Lens Anterior Eye 2012; 35:53-64. [DOI: 10.1016/j.clae.2011.12.005] [Citation(s) in RCA: 119] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2010] [Revised: 12/18/2011] [Accepted: 12/24/2011] [Indexed: 11/19/2022]
|
2
|
Luensmann D, Jones L. Impact of fluorescent probes on albumin sorption profiles to ophthalmic biomaterials. J Biomed Mater Res B Appl Biomater 2010; 94:327-336. [PMID: 20574970 DOI: 10.1002/jbm.b.31655] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Bovine serum albumin (BSA) was conjugated to three organic fluorescent probes, 5-(4,6-dichloro-s-triazin-2-ylamino)fluorescein hydrochloride (DTAF), Rhodamine B isothiocyanate (RITC), and Lucifer yellow VS (LY). The protein sorption profile to one pHEMA-based (etafilcon A) and three silicone hydrogel (SH) contact lens types (lotrafilcon B, balafilcon A and senofilcon A) was determined using confocal laser scanning microscopy. In addition, all lenses were incubated in dye solutions containing the fluorescent probe alone; and in a separate experiment BSA accumulation was quantified using radiolabeling. The different fluorescent conjugates showed similar sorption profiles for the pHEMA-based lens, but marked differences for all SH lenses. Lotrafilcon B accumulated more protein on the surface as compared to the matrix, independent of the fluorescent probe used for conjugation. Protein sorption varied for senofilcon A, with DTAF-BSA sorbing primarily to the surface region, while the other conjugates penetrated in equal amounts into the matrix. Balafilcon A exhibited smaller differences between conjugates, with LY-BSA allowing the protein to fully penetrate the matrix, while the other conjugates showed minor surface adsorption. Sorption curves of unbound dyes were often similar compared to the conjugated results. BSA profiles to pHEMA-based and silicone hydrogel lenses were highly dependent on the fluorescent probe used and none of the probes accurately reflected quantitative protein levels for the lens materials investigated.
Collapse
Affiliation(s)
- Doerte Luensmann
- School of Optometry, Centre for Contact Lens Research, University of Waterloo, Waterloo, Ontario N2L3G1, Canada.
| | | |
Collapse
|
4
|
Selvam S, Thomas PB, Hamm-Alvarez SF, Schechter JE, Stevenson D, Mircheff AK, Trousdale* MD. Current status of gene delivery and gene therapy in lacrimal gland using viral vectors. Adv Drug Deliv Rev 2006; 58:1243-57. [PMID: 17056149 PMCID: PMC1773022 DOI: 10.1016/j.addr.2006.07.021] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2006] [Accepted: 07/31/2006] [Indexed: 12/22/2022]
Abstract
Gene delivery is one of the biggest challenges in the field of gene therapy. It involves the efficient transfer of transgenes into somatic cells for therapeutic purposes. A few major drawbacks in gene delivery include inefficient gene transfer and lack of sustained transgene expression. However, the classical method of using viral vectors for gene transfer has circumvented some of these issues. Several kinds of viruses, including retrovirus, adenovirus, adeno-associated virus, and herpes simplex virus, have been manipulated for use in gene transfer and gene therapy applications. The transfer of genetic material into lacrimal epithelial cells and tissues, both in vitro and in vivo, has been critical for the study of tear secretory mechanisms and autoimmunity of the lacrimal gland. These studies will help in the development of therapeutic interventions for autoimmune disorders such as Sjögren's syndrome and dry eye syndromes which are associated with lacrimal dysfunction. These studies are also critical for future endeavors which utilize the lacrimal gland as a reservoir for the production of therapeutic factors which can be released in tears, providing treatment for diseases of the cornea and posterior segment. This review will discuss the developments related to gene delivery and gene therapy in the lacrimal gland using several viral vector systems.
Collapse
Affiliation(s)
- Shivaram Selvam
- Department of Chemical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA 90089, USA
- Ocular Surface Center, Doheny Eye Institute, Los Angeles, CA 90033, USA
| | - Padmaja B. Thomas
- Ocular Surface Center, Doheny Eye Institute, Los Angeles, CA 90033, USA
| | - Sarah F. Hamm-Alvarez
- Department of Pharmaceutical Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
- Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
- Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Joel E. Schechter
- Ocular Surface Center, Doheny Eye Institute, Los Angeles, CA 90033, USA
- Department of Cell and Neurobiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Douglas Stevenson
- Ocular Surface Center, Doheny Eye Institute, Los Angeles, CA 90033, USA
| | - Austin K. Mircheff
- Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
- Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | - Melvin D. Trousdale*
- Ocular Surface Center, Doheny Eye Institute, Los Angeles, CA 90033, USA
- Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
- Corresponding Author: Doheny Eye Institute, 1450 San Pablo Street, #204, Los Angeles, CA, 90033 USA, Tel.: +1 323 442 6610, Fax: +1 323 442 6688, E-mail: (Melvin D. Trousdale)
| |
Collapse
|